Login to Your Account

Time to Share? Cerezyme's Sole Reign in Gaucher Coming to End

By Jennifer Boggs

Friday, February 12, 2010
With the FDA set to make a decision on Shire plc's enzyme replacement therapy velaglucerase by the end of this month and a review date for Protalix Biotherapeutics Inc.'s Uplyso (taliglucerase alfa) expected later this year, Genzyme Corp.'s top-selling drug for Gaucher disease is certain to take a sales hit. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription